ProKidney Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.8%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.54next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 12 Nov 2026 |
| Q4 and Full Year 2026 Financial Results | 15 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Phase 3 PROACT 1 (REGEN-006) Trial Enrollment QuarterlyTarget: Approximately 470 subjects
Cash and Marketable Securities Balance Quarterly224.9MTarget: Sufficient to fund operations into mid-2027
Quarterly Research and Development (R&D) Expenses Quarterly33.8MTarget: Reflective of active Phase 3 clinical and manufacturing operations
Watch Items
- Pivotal eGFR slope topline results from Phase 3 PROACT 1 trialTrigger: Q2 2027Action: Evaluate clinical efficacy against the FDA-agreed effect size of at least 1.5 mL/min/1.73m²/year improvement versus sham control.
- Completion of Phase 3 PROACT 1 trial enrollmentTrigger: Mid-to-late 2026Action: Confirm enrollment completion to secure the timeline for the Q2 2027 surrogate endpoint readout.
- Cash runway sufficiencyTrigger: Below $100 million or less than 12 months of runwayAction: Assess capital raising options (e.g., ATM facility, secondary offerings, or strategic partnerships) to extend runway past the Q2 2027 readout.
Research as of 19 Jun 2026